Seeking Alpha

Seeking Alpha Portfolio App for iPad

2,017 people get GERN articles and Market Currents by email alert.

Get email alerts on GERN »

GERN

Geron Corporation

5/24/2013, 11:55 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 23, 1:48 PM BioTime (BTX -0.2%) says its shareholders have overwhelmingly approved the planned acquisition of stem cell-related assets from Geron (GERN). The green light was given at a special meeting of shareholders, with at least 32.5M votes coming in favor from the 34.5M shares represented and voted. Comment! [Healthcare, M&A]
Friday, April 26, 10:48 AM Geron (GERN -5%) slips after posting a mixed Q1 report late yesterday that came up short on its bottom line. The company also announced plans to cut its workforce by about a third and discontinue its discovery research and companion diagnostics programs, as the pharmaceutical company plans to put its entire focus on the development of Imetelstat, a treatment for hematologic myeloid malignancies. 1 Comment [Healthcare, On the Move, Earnings]
Thursday, April 25, 5:04 PM Geron (GERN): Q1 EPS loss of $0.09 misses by $0.01. Revenue of $765M beats by $55M. (PR). Comment! [Healthcare, Earnings, Breaking News]
Thursday, April 25, 12:10 AM Notable earnings after Thursday’s close: AEM, ALTR, AMCC, AMKR, AMZN, BIDU, BJRI, BLDR, BMRN, CALX, CAMP, CB, CBG, CENX, CERN, CINF, CLWR, CRUS, CSTR, CTCT, DECK, DLB, ELY, EMN, EXPE, FII, FR, FSL, GERN, IGT, IM, INAP, INFA, KBR, KEG, KLAC, LEG, MCRS, MXIM, N, NR, NTGR, OLN, PFG, PKI, PMCS, QLIK, RMD, RRC, RSG, SBUX, SIMO, SPN, SWKS, SYNA, TCO, THRX, TLAB, UHS, VPRT, VRSN, WRE, WYNN Comment! [Earnings]
Wednesday, April 24, 5:35 PM Notable earnings after Thursday’s close: AEM, ALTR, AMCC, AMKR, AMZN, BIDU, BJRI, BLDR, BMRN, CALX, CAMP, CB, CBG, CENX, CERN, CINF, CLWR, CRUS, CSTR, CTCT, DECK, DLB, ELY, EMN, EXPE, FII, FR, FSL, GERN, IGT, IM, INAP, INFA, KBR, KEG, KLAC, LEG, MCRS, MXIM, N, NR, NTGR, OLN, PFG, PKI, PMCS, QLIK, RMD, RRC, RSG, SBUX, SIMO, SPN, SWKS, SYNA, TCO, THRX, TLAB, UHS, VPRT, VRSN, WRE, WYNN Comment! [Earnings]
Tuesday, April 9, 9:33 AM Geron (GERN -4.3%) looks like it will be unable to use its imetelstat drug for treating lung-cancer patients after final results from a Phase II study confirm that the medicine was ineffective in a sub-group of patients in which initial results had looked promising. (PR) 1 Comment [Healthcare]
Thursday, March 14, 10:49 AM Shares of Geron (GERN -6.1%) get slammed today, despite posting a solid Q4 report after yesterday's close. Revenues soared by nearly 175% from the prior year period, easily topping consensus estimates. However, concerns over an ongoing investigation into lab value abnormalities from its essential thrombocythemia study, plus opaque visibility on imetelstat progress have prompted a number of firms to cut their ratings. Piper Jaffray downgraded the shares to Overweight, while mid-day yesterday Stifel Nicolaus went even further, cutting the shares to sell. Comment! [Healthcare, Earnings, On the Move]
Tuesday, March 12, 5:07 PM Geron (GERN): Q4 EPS of -$0.12 beats by $0.02. Revenue of $689K beats by $189K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, March 12, 12:10 AM Notable earnings after Tuesday’s close: DOLE, GERN, HRZN, IRET, KTOS, PPHM, VELT Comment! [Earnings]
Monday, March 11, 5:35 PM Notable earnings after Tuesday’s close: DOLE, GERN, HRZN, IRET, KTOS, PPHM, VELT 2 Comments [Earnings]
Friday, January 18, 9:17 AM Geron (GERN) +5.4% after an upgrade to Buy with $3 price target by Piper Jaffray's Charles Duncan. The current price of $1.66 reflects past challenges, he says, but leaves room for substantial upside over the course of the next year. That Geron and INO are buys at Piper while ZIOT and THLD are Holds does not compute, says Dan Rosenblum. Sell-side games, says TheStreet's Adam Feuerstein. 1 Comment [Healthcare, On the Move]
Friday, January 18, 9:10 AM Premarket gainers: PATH +16%. LIFE +12%. NEWL +8%. RIMM +8%. MS +7%. SNE +7%. GERN +5%.
Losers: FNSR -10%. TSRX -9%. WIT -8%. COF -7%. INTC -6%.
2 Comments [On the Move]
Monday, January 7, 1:15 PM Shares of Geron (GERN +2.5%) snd BioTime (BTX +7.6%) both rise today after BTX agrees to buy the intellectual property, including patents and patent applications, and other assets related to GERN's human embryonic stem cell programs. The financial terms of the deal were in a letter of intent announced back in mid-November. Comment! [Healthcare, M&A, On the Move]
Monday, December 10, 2012, 12:45 PM Midday top 10 gainers: CBMX +37%. UNXL +37%. ACUR +32%. GERN +25%. IN +23%. CLDX +23%. GPRC +20%. TELK +19%. SUMR +17%. EJ +16%.
Midday top 10 Losers: ZGNX -47%. CSFS -25%. MEAD -13%. TCCO -12%. GTIM -11%. SEV -10%. GEO -10%. BLIN -10%. DCTH -9%. NQ -9%. Comment! [On the Move]
Monday, December 10, 2012, 9:34 AM Geron (GERN) soars 15.1% after saying that its imetelstat treatment performed well in Phase II trials of patients with a chronic blood disorder called essential thrombocythemia. Geron designed the trial to provide a proof of concept for the potential use of imetelstat to treat blood cancers. Geron shares were slammed last week after it said it was stopping the development of therapies for brain cancer. (Presentation) 1 Comment [Healthcare]
Monday, December 10, 2012, 9:10 AM Premarket gainers: IN +23%. GERN +17%. NXY +15%. CLDX +10%. STSI +7%. AAV +7%.
Losers: ZGNX -39%. CBMX -18%. DMND -5%. Comment! [On the Move]